ClinicalTrials.Veeva

Menu

Elucidate Vasodilatory Capacity From Histology-Defined Analysis of Coronary CT Angiography (HD-FFRct)

E

Elucid Bioimaging

Status

Completed

Conditions

Vascular Diseases

Treatments

Device: ElucidVivo

Study type

Observational

Funder types

Other
Industry

Identifiers

NCT05524896
HD-FFRct

Details and patient eligibility

About

Coronary CT Angiography (CCTA) may be an ideal modality to fill gaps in understanding the extent and rate of progression coronary artery disease. The investigators have developed an image analysis software ElucidVivo that estimates relevant indices, including fractional flow reserve (FFR) . In this study, the investigators aim to assess the value of ElucidVivo-based plaque morphology characterization for predicting non-invasive FFR in patients with suspected coronary artery disease (CAD) who had undergone clinically indicated coronary CTA and invasive coronary angiography (ICA) for physical FFR measurement.

Full description

Invasive FFR is a clinically validated measure of lesion-specific ischemia and is preferred over visual estimation of diameter stenosis for clinical decisions regarding coronary revascularization. FFR derived from coronary CTA (FFRct) using computational fluid dynamics (CFD)-based software has been shown to be a reasonably accurate estimate of invasive FFR and is included in contemporary guidelines as a decision-tool for management of patients with intermediate stenosis on coronary CTA. However, other methods have limitations. It is understood that the burden and type of coronary atherosclerosis, in addition to lumen stenosis, significantly impacts the vasodilatory capacity of the vessel walls which may provide a more interpretable analysis and broader clinical acceptance.

Enrollment

302 patients

Sex

All

Ages

18+ years old

Volunteers

No Healthy Volunteers

Inclusion criteria

  • Subject must have successfully completed at least one (possibly multiple) CCTA for known or suspected coronary artery disease.
  • CCTA was no more than 60 days earlier (and not later)

Exclusion criteria

  • Subject has a history of percutaneous coronary intervention (PCI) with stent implantation and/or coronary artery bypass grafting (CABG)
  • Subject with insufficient CCTA image quality (defined strictly as documented in the ElucidVivo Reading Manual)

Trial design

302 participants in 2 patient groups

Low FFR
Description:
Invasive FFR value \<= 0.8
Treatment:
Device: ElucidVivo
High FFR
Description:
Invasive FFR value \> 0.8
Treatment:
Device: ElucidVivo

Trial contacts and locations

0

Loading...

Data sourced from clinicaltrials.gov

Clinical trials

Find clinical trialsTrials by location
© Copyright 2026 Veeva Systems